A naukri.com initiative
Bioengineer
1w
206
Image Credit: Bioengineer
New Peptide Drug Shows Promise in Fighting Deadly Brain Cancer, Researchers Reveal
- Researchers at Virginia Tech's Fralin Biomedical Research Institute have developed a promising peptide drug named JM2 to target glioblastoma stem cells, known for tumor recurrence post-treatments.
- Glioblastoma stem cells pose a challenge due to their treatment resistance, leading to tumor regeneration and relapse, highlighting JM2's significance in improving patient outcomes.
- JM2 disrupts connexin 43-microtubule interactions selectively within glioblastoma stem-like cells, inducing cell death without harming healthy brain tissue.
- Preliminary studies show JM2's efficacy in shrinking gliospheres and suppressing tumor growth in animal models, suggesting potential clinical application in glioblastoma therapy.
- This groundbreaking research uncovers a new role of connexin 43 in supporting glioblastoma stem cells' maintenance and tumorigenicity, offering a novel therapeutic target.
- The interdisciplinary collaboration between institutions like Virginia Tech and Carilion Clinic enables translational research to address the challenges of glioblastoma treatment resistance.
- Future research will focus on optimizing JM2 delivery mechanisms to target glioblastoma cells effectively, potentially revolutionizing treatment strategies for this aggressive brain cancer.
- JM2's commercialization through Acomhal Research Inc. reflects the translational potential of academic discoveries, aiming to provide new targeted therapies for cancer patients.
- The discovery and development of JM2 offer a promising avenue for transforming glioblastoma treatment paradigms, potentially enhancing patient survival rates and quality of life.
- JM2's specificity in targeting resistant cancer stem-like cells while preserving normal brain cells underscores its potential as an innovative peptide-based therapeutic option.
Read Full Article
12 Likes
For uninterrupted reading, download the app